BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05562934 (XXB750 in Resistant Hypertension): BVCT ex-ante prediction vs. reported outcome

On 1 Jul 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 31 Jan 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05562934
Drug Name
XXB750
Drug MoA
long-acting NPR1 agonist
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Cardiovascular Diseases
Indication
Resistant Hypertension
Human Patients
191
Sponsor
Novartis
Phase
Phase 2

Prediction of , index 1657

Prospective Prediction
Prediction Index
1657
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in mean 24hr SBP at week 12 inferior to baxdrostat)
Technical Prediction
partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in mean 24hr SBP at week 12 with moderate toxicity)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
214 days in advance
Readout Data Interpretation
XXB750 hasn't met the efficacy threshold and further development discontinued without disclosure of data
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
Phase
Phase 2
Status
Completed
Enrollment
189
Lead sponsor
Novartis Pharmaceuticals
Conditions
Resistant Hypertension
Interventions
BIOLOGICAL: XXB750 drug; OTHER: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2022-11-08
Primary completion
2024-07-02
Completion
2024-08-27
Results first posted
2025-10-24
Primary outcomes
  • Dose-response (DR) Relationship of XXB750 With Respect to Change From Baseline in Systolic Blood Pressure (SBP) 24 Hours (Baseline, Week 12)

NCT05562934 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials